Combining cell therapy with human autologous Schwann cell and bone marrow-derived mesenchymal stem cell in patients with subacute complete spinal cord injury: safety considerations and possible outcomes.
Saeed Oraee-YazdaniMohammadhosein AkhlaghpasandMaryam GolmohammadiMaryam HafiziMina Soufi ZomorrodNima Mohseni KabirMaryam Oraee-YazdaniFarzad AshrafiAlireza ZaliMasoud SoleimaniPublished in: Stem cell research & therapy (2021)
The present study showed that autologous SC and bone marrow-derived MSC transplantation at the subacute stage of SCI could reveal statistically significant improvement in sensory and neurological functions among the patients. It appears that using this combination of cells is safe and effective for clinical application to spinal cord regeneration during the subacute period.
Keyphrases
- cell therapy
- mesenchymal stem cells
- spinal cord injury
- stem cells
- spinal cord
- end stage renal disease
- bone marrow
- umbilical cord
- endothelial cells
- neuropathic pain
- induced apoptosis
- newly diagnosed
- chronic kidney disease
- ejection fraction
- single cell
- endoplasmic reticulum stress
- cell cycle arrest
- blood brain barrier
- patient reported outcomes
- induced pluripotent stem cells